# CorMedix Inc. (CRMD) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.56, market value $433 million.

## Valuation
- **P/E (trailing): 2.7×** (5-yr avg 5.7×, 3-yr avg 5.7×). CorMedix Inc. trades at 2.7× trailing earnings, well below its own five-year average of 5.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.9×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.02**. A PEG of 0.02 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.9×**. Each dollar of revenue is priced at 0.9×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.9×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Free-cash-flow yield: 57.8%** (5-yr avg -8.0%). Free cash flow equals 57.8% of the market value, above its five-year average of -8.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 36.9%**. The inverse of the P/E: 36.9% of the price is earned each year.

## Profitability
- **Gross margin: 82.8%**. CorMedix Inc. keeps 82.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 47.0%**. 47.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 52.3%**. 52.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 40.2%**. 40.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 22.7%**. Each dollar of assets produces 22.7% of profit.

## Growth
- **Revenue growth (1 yr): 617.0%** (3-yr 1582.8%/yr, 5-yr 319.7%/yr). Revenue grew 617.0% over the last year, against 319.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 780.0%**. Earnings per share rose 780.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 2.11** (quick 2.11). Current assets cover the next year's liabilities 2.11 times.
- **Altman Z-score: 2.56**. A Z-score of 2.56 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. CorMedix Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover CorMedix Inc.; the consensus is strong_buy, with an average price target of $15.33 (+176% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -51.6%** (YTD -53.7%, 3-mo -28.6%). The shares are down 51.6% over twelve months including dividends.
- **From 52-week high: -57.3%** (4.9% above the low). Trading 57% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 23**. An RSI of 23 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.39** (volatility 64%). Beta of 1.39 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRMD · Page: https://foliofundamentals.com/stocks/crmd

Not investment advice.